Anbio Biotechnology Cash and Restricted Cash
Anbio Biotechnology (NNNN) had Cash and Restricted Cash of $7.77 million as of 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-04-07
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.77M.
- 2024-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.76M.
- 2023-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.69M.
- 2022-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2025-12-31 | $7.77M 20-F · filed 2026-04-07 |
| 2024-12-31 | $11.76M 20-F · filed 2026-04-07 |
| 2023-12-31 | $9.69M 20-F · filed 2026-04-07 |
| 2022-12-31 | $7.10M 20-F · filed 2026-04-07 |
| 2021-12-31 | $4.18M 20-F · filed 2025-04-28 |